Literature DB >> 15202017

Expression of CXCL16 in human rectal cancer.

Dick Wågsäter1, Anders Hugander, Jan Dimberg.   

Abstract

Local immunoregulation mediated by infiltration of inflammatory cells into colorectal adenocarcinomas is important for tumour progression. Tumour-associated macrophages and T cells are predominant components of chemokine-guided infiltrate of most colorectal tumours. CXCL16 is a newly discovered CXC chemokine expressed by antigen presenting cells attracting Th1, Tc and NK T cells. In this study, which is the first report on expression of the chemokine CXCL16 in human rectal cancer, CXCL16 gene and protein expression were analysed in cancer and normal adjacent tissue. Immunohistochemistry revealed CXCL16 expression in macrophages in normal tissue. The CXCL16 was found to a very limited extent in tumour-associated macrophages. Western blot analysis showed a suppression of CXCL16 protein in rectal cancer compared to non-cancer tissue in 83% of the patients (n=23, P=0.003). However, with real-time PCR mRNA was not down-regulated in the cancer compared to normal tissue, which may depend on regulated factor(s) at the level of translation and/or post-translation. The results may reflect one of the immunological mechanisms underlying carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202017

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis.

Authors:  Gabriela E Garcia; Luan D Truong; Ping Li; Ping Zhang; Richard J Johnson; Curtis B Wilson; Lili Feng
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

2.  Akt1 governs breast cancer progression in vivo.

Authors:  Xiaoming Ju; Sanjay Katiyar; Chenguang Wang; Manran Liu; Xuanmao Jiao; Shengwen Li; Jie Zhou; Jacob Turner; Michael P Lisanti; Robert G Russell; Susette C Mueller; John Ojeifo; William S Chen; Nissim Hay; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

3.  LysoPtdOH enhances CXCL16 production stimulated by LPS from macrophages and regulates T cell migration.

Authors:  Shijun Kang; Chunlan Yang; Rongcheng Luo
Journal:  Lipids       Date:  2008-10-02       Impact factor: 1.880

4.  "Inverse signaling" of the transmembrane chemokine CXCL16 contributes to proliferative and anti-apoptotic effects in cultured human meningioma cells.

Authors:  Kirsten Hattermann; Kareen Bartsch; Henrike H Gebhardt; H Maximilian Mehdorn; Michael Synowitz; Anne Dorothée Schmitt; Rolf Mentlein; Janka Held-Feindt
Journal:  Cell Commun Signal       Date:  2016-10-27       Impact factor: 5.712

5.  Elevated expression of CXCL16 correlates with poor prognosis in patients with colorectal cancer.

Authors:  Zhihui Chen; Weigang Dai; Liang Yang; Hong Yang; Li Ding; Yulong He; Xinming Song; Ji Cui
Journal:  Cancer Manag Res       Date:  2019-05-23       Impact factor: 3.989

6.  CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-α-induced apoptosis by tumor-associated macrophages.

Authors:  Ji-Ye Kee; Aya Ito; Shozo Hojo; Isaya Hashimoto; Yoshiko Igarashi; Koichi Tsuneyama; Kazuhiro Tsukada; Tatsuro Irimura; Naotoshi Shibahara; Ichiro Takasaki; Akiko Inujima; Takashi Nakayama; Osamu Yoshie; Hiroaki Sakurai; Ikuo Saiki; Keiichi Koizumi
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

7.  Trophoblast-derived CXCL16 induces M2 macrophage polarization that in turn inactivates NK cells at the maternal-fetal interface.

Authors:  Xiao-Qiu Wang; Wen-Jie Zhou; Xin-Xin Hou; Qiang Fu; Da-Jin Li
Journal:  Cell Mol Immunol       Date:  2018-03-27       Impact factor: 11.530

Review 8.  The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases.

Authors:  Jan Korbecki; Karolina Bajdak-Rusinek; Patrycja Kupnicka; Patrycja Kapczuk; Donata Simińska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.